drugset / Trial / NCT00396227

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

NCT00396227

Phase 3 Completed 2665 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate, in a primary care setting, the safety and efficacy of vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients with type 2 diabetes inadequately controlled by metformin alone.

Timeline

Start
2006-10
Primary completion
2007-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pioglitazone Small molecule
Comparator Rosiglitazone Small molecule
Subject Vildagliptin Other / unclassified 100 mg